Billionaire Joe Edelman’s 5 Stock Picks with Huge Upside Potential

4. Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Perceptive Advisors’ Stake: $100 Million

Analyst Upside Potential: 88%

Following a string of clinical successes in early April, Spyre Therapeutics, Inc. (NASDAQ:SYRE) stock has become a favorite for managers looking to capitalize on the multi-billion dollar Inflammatory Bowel Disease market. A major catalyst for the shares was the recent announcement of Part A induction results from the Phase 2 SKYLINE trial for SPY001. The drug met its primary endpoint in patients with moderate-to-severe ulcerative colitis. The trial showed a 40% clinical remission rate at Week 12, which analysts from Goldman Sachs noted is potentially superior to currently available treatments like Entyvio. The data confirmed a pharmacokinetic profile that could allow for quarterly or even biannual subcutaneous dosing, a massive convenience advantage over the monthly or bi-monthly schedules of competitors.

Spyre Therapeutics, Inc. (NASDAQ:SYRE) has a unique strategy of combining best-in-class antibodies. Beyond SPY001, Spyre is developing long-acting antibodies targeting TL1A and IL-23. Hedge funds believe the real blockbuster potential lies in Spyre’s plan to test these antibodies in combination. Analysts estimate that successful combination therapies could redefine the standard of care in a global IBD market projected to reach $50 billion annually. Given the high efficacy and dosing convenience of its lead assets, many elite money managers view Spyre as a prime acquisition target for Big Pharma players like AbbVie or Takeda looking to defend their IBD franchises.